SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

QuotedData's Weekly News & Interview

26 Jan 2023 11:32

RNS Number : 9947N
RTW Venture Fund Limited
26 January 2023
 

QuotedData's Investment Trust Weekly News Round-up Show - Stephanie Sirota from RTW Venture Fund

On the 20th January, James Carthew talked through the Weekly News and interviewed Stephanie Sirota from RTW Venture Fund - Watch here.

About our Weekly Show:

The best way to enjoy the show is to join our weekly webinar live, at 11 am every Friday, where we discuss the key stories and events in the investment companies' sector over the last week. We also invite a guest every week and give you the opportunity to get answers to your questions.

Click here to view our previous recordings: https://quoteddata.com/events/?past=true

Click here to view our upcoming events: https://quoteddata.com/events/

This information is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

This website is for information purposes only and is not intended to encourage the reader to deal in any mentioned securities. QuotedData is a trading name of Marten & Co Limited, which is authorised and regulated by the Financial Conduct Authority. Some of the content in this website is sponsored and, although it abides by Content Principles and Objectives, (/about-quoteddata/research-principles-objectives/) it is considered non-independent. Investments may involve a significant degree of risk, including loss of capital. The value of an investment and the income from it could go down as well as up. The return of your investment is not guaranteed, and you may get back less than you originally invested. Past performance is not an indicator of future performance. It is important that you read the Terms and Conditions (/about-quoteddata/terms-and-conditions/) before considering any investment.

QUOTEDDATA50 Gresham Street | London | EC2V 7AY | UKTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBGDBGXDDGXL
Date   Source Headline
13th Feb 20267:00 amRNSMonthly Valuation Update and Factsheet
23rd Jan 20267:00 amRNSCorxel completes $287 million Series D-1 financing
22nd Jan 202610:00 amRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSGSK to acquire RAPT Therapeutics
16th Jan 20267:00 amRNSBoston Scientific to acquire Penumbra
15th Jan 20267:00 amRNSMonthly Valuation Update and Factsheet
12th Jan 20267:00 amRNSAktis announces $318 million IPO
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
18th Dec 20257:00 amRNSNew investment in Yarrow Bioscience
12th Dec 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSInclusion in FTSE 250 Index
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20256:00 pmRNSSpectris
1st Dec 20257:00 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20252:30 pmRNSTransaction in Own Shares
25th Nov 202512:00 pmRNSRetail Investor Webinar
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSMonthly Valuation Update and Factsheet
7th Nov 20257:00 amRNSEvommune announces $150 million IPO
5th Nov 202510:00 amRNSHolding(s) in Company
3rd Nov 20259:33 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSRoyalty Funding Agreement with Savara Inc.
29th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSNovartis to acquire Avidity Biosciences
20th Oct 20257:00 amRNSCapital Allocation Plan based on M&A successes
15th Oct 20257:00 amRNSKailera Therapeutics announces Series B financing
14th Oct 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Oct 20257:00 amRNSNovo Nordisk to acquire Akero Therapeutics
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20257:01 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSGenmab to acquire Merus
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:01 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSBiogen to acquire Alcyone Therapeutics
15th Sep 20257:00 amRNSMonthly Valuation Update and Factsheet
11th Sep 20257:00 amRNSHalf-year Report
5th Sep 20257:00 amRNSInclusion in FTSE All-Share Index
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:01 amRNSNotice of Interim Results
19th Aug 20257:00 amRNSStrategic Funding Agreement with Aquestive
15th Aug 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.